Print

VRC 602

VRC 602: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIV MAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) November 01, 2013
VRC-HIVMAB060-00-AB VRC01 Antibody
VRC-HIVMAB060-00-AB Passive Immunization
USA 29
NCT01993706
https://clinicaltrials.gov/ct2/show/study/NCT01993706